Efficacy and safety of HLA-B7/β-2 microglobulin plasmid DNA/lipid complex (Allovectin-7^®) in patients with metastatic melanoma

Bibliography

• RIGEL DS, FRIEDMAN RJ, KOPF AW: The incidence of malignant melanoma in the United States: issues as we approach the 21st century. J. Am. Acad. Dermatel (1996) 34(5 Pt 1):839–847.
   Google Scholar
• JEMAL A, THOMAS A, MURRAY T, THUN MM: Cancer statistics 2002. CA Cancerj Clin (2002) 52:23–47.
   PubMed Web of Science ®Google Scholar
• RIGEL DS, CARUCCI JA: Malignant melanoma: prevention, early detection and prevention in the 21st century. CA Cancer Clin (2000) 50:215–236.
   PubMed Web of Science ®Google Scholar
• HALL HI, MILLER DR, ROGERS JD, BEWERSE B: Update on the incidence and mortality from melanoma in the United States. J. Am. Acad. Dermatel (1999) 40:35–42.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS, SMITH TJ, BORDEN EC, BLUM RH: Interferon alfa-26 adjuvant therapy of high-risk resected cutaneous melanoma: theEastern Cooperative Oncology Group Trial EST 1684. J. Cliii. Once' (1996)14(1):7–17.
   PubMed Web of Science ®Google Scholar
• •The ECOG 1684 trial used 1 year of high-dose IFN and showed statistically significant overall and disease-free survival benefits for patients with lesions 4 mm depth, or with positive lymph nodes, compared to the no additional treatment group.
   Google Scholar
• KEILHOLZ U, EGGERMONT AM: The role of interleukin-2 in the management of stage IV melanoma; the EORTC melanomacooperative group program. Canc. J. Sci. Am. (2000) 6\(Suppl. 1):S99–S103.
   Google Scholar
• MIDDLETON MR, GROB JJ, AARONSON N et al.: Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.' Clin. Oncol (2000) 18(1):158–166.
   Google Scholar
• BRODER S, WALDMAN TA: The suppressor-cell network in cancer. N Engl. J. Med. (1978) 299(23):1281–1284.
   PubMed Web of Science ®Google Scholar
• LOEFFLER CM, SMYTH MJ,LONGO DL et al.: Immunoregulation in cancer-bearing hosts. Down regulation of gene expression and cytotoxic function in CD8+ T cells. J. Immunol (1992) 149(3):949–956.
   Google Scholar
• HICKLIN DJ, WANG Z, ARIENTI et al: Beta2-microglobulin mutations, HLA classI antigen loss, and tumor progression in melanoma. J. Clin. Invest. (1998)101(12):2720–2729.
   PubMed Web of Science ®Google Scholar
• NOURI AM, HUSSAIN RF, DOS SA, MANSOURI M, OLIVER RT: Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing. Br. I. Cancer (1993) 67:1223–1228.
   PubMed Web of Science ®Google Scholar
• TANAKA K, ISSELBACHER KJ, KHOURY G et al.: Reversal of oncogenesis by expression of a major histocompatibility complex class I gene. Science (1985) 228(4695):26–30.
   PubMed Web of Science ®Google Scholar
• HILL GJ, KREMENTZ ET, HILL HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer (1984) 53(6):1299–1305.
   Google Scholar
• BUZAID AC, LEGHA S, WINN R et al: Cisplatin, vinblastine, and dacarbazine (CVD) versus dacarbazine alone in metastatic melanoma; preliminary results of a Phase II cancer community oncology program (CCOP) trial (abstract). Proc. Am. Soc. Clin. Oncol (1993) 12:389.
   Google Scholar
• CHAPMAN PB, EINHORN LH, MEYERS ML et al.: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol (1999) 17(9):2745–2751.
   PubMed Web of Science ®Google Scholar
• MIDDLETON MR, LORIGAN P, OWEN J et al: A randomized Phase III study comparing dacarbazine, BCNU,cisplatin and tamoxifen with dacarbazineand interferon in advanced melanoma. Br: J. Cancer (2000) 82(6):1158–1162.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, IBRAHIM JG, SONDAK VK et al: High- and low-dose interferon alfa-26 in high-risk melanoma: first analysis of Intergroup Trial E1690/ 59111/C9190. Clin. Oncol (2000) 18(12):2444–2458.
   Web of Science ®Google Scholar
• WHEATLEY K, HANCOCK B, GORE M, SUCIU S,EGGERIVIONT AMM: Interferon-alpha as adjuvant therapy for melanoma: a meta-analysis of the randomized trials. [abstract]. Proc. Am. Soc. Clin. Oncol (2001) 20:1394.
   Google Scholar
• LENS MB, DAWES M: Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials.j Clin. Oncol (2002) 20:1818–1825.
   Google Scholar
• •A somewhat controversial systematic review of most major interferon trials in melanoma.
   Google Scholar
• KIRKWOOD JM, IBRAHIM J, ERNSTOFF MS, FLAHERTY L, HALUSKA FJ; WHEALTELY K, IVES N, HANCOCK B, GORE M;SEIDMAN AD, PIERI MK, HUDIS C; LENS MB, DAWES M: Correspondence: Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma; Replies; Use and abuse of statistics in evidence-based medicine." Clin. Oncol (2002) 20:4119–4124.
   PubMedGoogle Scholar
• KIRKWOOD JM, IBRAHIM JG, SOSMAN JA et al.: High-dose interferon alfa-26 significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of Intergroup trial E1694/S9512/C509801.Clin. Oncol (2001) 19:2370–2380.
   Google Scholar
• FALKSON CI, FALKSON G,FALKSON HC: Improved results with the addition of interferon alpha-2b to dacarbazine in the treatment of patients with metastatic melanoma. J. Clin. Oncol (1991) 9:1403–1408.
   PubMed Web of Science ®Google Scholar
• FALKSON CI, IBRAHIM J, KIRKWOOD JM, COATES AS, ATKINS MB, BLUM R: Phase II trial of dacarbazine versus dacarbazine with interferon alpha2b versus dacarbazine with tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology study." Clin. Oncol (1998) 16:1743–1751.
   PubMed Web of Science ®Google Scholar
• ATKINS MB, LOTZE MT, DUTCHER JP et al.: High-doserecombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.j Clin. Oncol (1999) 17:2105–2116.
   Google Scholar
• ATKINS MB, KUNKEL L, SZNOL M, ROSENBERG SA: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancerj Sci. Am. (2000)6\(Suppl. 1):S11.
   Google Scholar
• •Larger trial using high-dose IL-2 in metastatic melanoma, resulting in 6% CRs and 4% durable CRs lasting 70+ to 150+ months.
   Google Scholar
• ROYAL RE, STEINBERG SM, KROUSE RS et al.: Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancerj Sci. Am. (1996) 2:91.
   PubMedGoogle Scholar
• LEGHA SS, RING S, BEDIKIAN A et al.: Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine and biotherapy using interlukin-2 and interferon-alpha. Ann. Oncol (1996) 7(8):827–835.
   PubMed Web of Science ®Google Scholar
• MCDERMOTT DF, MEIR JW, LAWRENCE DP et al.: A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2b in patients with metastatic melanoma. Clin. Cancer Res. (2000) 6(6):2201–2208.
   PubMed Web of Science ®Google Scholar
• LEGHA SS, RINGS, ETON 0 et al: Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alpha, and interleukin-2 for patients with metastatic melanoma. " Clin. Oncol (1998) 16:1752–1759.
   PubMed Web of Science ®Google Scholar
• •Small trial using concurrent biochemotherapy which resulted in significant response rates and 9% durable CRs in metastatic melanoma.
   Google Scholar
• FLAHERTY LE: Rationale for Intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma. Cancer J. Sci. Am. (2000) 6\(Suppl. 1):515–520.
   Google Scholar
• NESTLE FO, BANCHEREAU J, HART D: Dendritic cells: on the move from the bench to the bedside. Nat. Med. (2001) 7:761–765.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatmentof patients with metastatic melanoma. Nat. Med. (1998) 4(3):321–327.
   PubMed Web of Science ®Google Scholar
• BELLI F, TESTORI A, RIVOLTINI L et al.: Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp-96-peptide complexes: clinical and immunologic findings. 1. Clin. Omni (2002) 20(20):4169–4180.
   Google Scholar
• HSUEH E, ESSNER R, FOSHAG L et al.: Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. .1 Clin. Oncol. (2002) 20(23)4549–4554.
   Google Scholar
• BANCHEREAU J, PALUCKA AK, DHODAPKAR M et al.: Immune and clinical response in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. (2000) 61:6451–6458.
   Web of Science ®Google Scholar
• NAWROCKI S, WYSOCKI PJ, MACKIEWICZ A: Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer. Expert Opin. Biol. Ther. (2001) 1(2):193–204.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANNELLI JR, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ,WEBER JS: Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl. Cancer Inst. (1994) 86(15):1159–1166.
   PubMed Web of Science ®Google Scholar
• YEE C, THOMPSON JA, ROCHE P, BYRD DR, LEE PE PIEPKORN M: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo. 1. Exp. Med. (2000) 192(11):1637–1644.
   Google Scholar
• DUDLEY ME, WUNDERLICH J, NISHIMURA MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. Immunother. (2001) 24(4):363–373.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, YANG JC, HWU P, SCHWARTZENTRUBER DJ, TOPALIAN SL: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patientswith metastatic melanoma. Immunother.(2002) 25(3):243–251.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850–854.
   PubMed Web of Science ®Google Scholar
• NAWROCKI S, MURAWA P, MALICKI J et al.: Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol. Lett. (2000) 74(1):81–86.
   PubMed Web of Science ®Google Scholar
• PHILIP PA, FLAHERY LE: Biochemotherapy for melanoma.Curr. Oncol. Rep. (2000) 2(4):314–321.
   Google Scholar
• ATKINS MB: The treatment of melanoma with chemotherapy and biologics. Carr: Opin. Omni (1997) 9(2):205–213.
   PubMedGoogle Scholar
• LEE ML, TOMSU K, VON ESCHEN KB: Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. (2000) 10(1):81–92.
   PubMed Web of Science ®Google Scholar
• WAGNER JD, GORDON MS, CHUANG TY, COLEMAN JJ 3RD: Current therapy of cutaneous melanoma. Plast. Reconsm. Surg. (2000) 105(5):1774–1799.
   PubMed Web of Science ®Google Scholar
• PARKER SE, VAHLSING HL,SERFILIPPI LM et al: Cancer gene therapy using plasmid DNA: safety evaluation in rodents and non-human primates.Hum. Gene The,: (1995) 6(5):575–590.
   Google Scholar
• LEW D, PARKER SE, LATIMER T et al.: Cancer gene therapy using plasmid DNA: pharmacokinetic study of DNA following injection in mice. Hum. Gene. Tiler. (1995) 6(5):553–564.
   PubMed Web of Science ®Google Scholar
• PARKER SE, DUCHARME S, NORMAN J, WHEELER CJ: Tissue distribution of the cytofectin component of a plasmid-DNA/cationic lipid complex following intravenous administration in mice. Hum. Gene Ther. (1997) 8(4):393–441.
   PubMed Web of Science ®Google Scholar
• STOPECK AT, HERSH EM, AKPORIAYE ET et al: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. Clin. Oncol. (1997) 15:341–349.
   Web of Science ®Google Scholar
• NABEL G, NABEL E, YANG Z et al: Direct gene transfer with DNA-liposomecomplexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Nati Acad. Sci. USA (1993) 90:11307–11311.
   PubMed Web of Science ®Google Scholar
• NABEL G, GORDON D, BISHOP DK et al.: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc. Nati Acad. Sci. USA (1996) 93:15388–15393.
   PubMed Web of Science ®Google Scholar
• SILVER HKB, KLASA RJ, BALLY JB et al: Phase I gene therapy study of HLA-B7 transduction by direct injection in malignant melanoma. Proc. AACR (1996) 37(342):3227 (Abstract).
   Google Scholar
• HERSH EM, FIGLIN R, GUTHEIL J et al.: Intratumoral gene transfer therapy of cancer. Mol. Eller. (2001) 3(5 Suppl.):S19.
   Google Scholar
• RICHARDS J, THOMPSON J, ATKINS MB et al.: A controlled, randomized Phase III trial comparing the response to dacarbazine with and without Allovectin-7 in patients with metastatic melanoma. ASCO Abstracts(2002)11380.
   Google Scholar
• STOPECK AT, JONES A, HERSH EM et al.: Phase II study of direct intralesional gene transfer of Allovectin-7, and HLA-B7/ B2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin. Cancer Res. (2001) 7:2285–2291.
   PubMed Web of Science ®Google Scholar
• ••Small trial using Allovectin-7 in patientswith metastatic melanoma, resulting in an overall response rate of 4% and stable disease in 18% lasting at least 11 weeks, with a relatively safe toxicity profile outside the adverse events experienced with intracavitary injections.
   Google Scholar